Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

Figure 2. Photographs of the tubular seep carbonate SQW-65. The dashed blue line represents the dividing line between zones B and C. The dashed yellow line represents the dividing line between zones B ...

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Existing approvals for Bristol Myers Squibb’s Opdivo and anti-CTLA4 agent Yervoy, plus Merck & Co.’s Keytruda, will be discussed. BeiGene’s two open applications for Tevimbra will also face ...

Merck’s Ebola vaccine offered substantial protection to people vaccinated during the 2018-2020 outbreak in the Democratic Republic of the Congo, with an effectiveness of 84% in those who had ...